Accera, Inc. to Moderate Symposium on Metabolic Dysregulation in Alzheimer's Disease During the 6th Annual Clinical Trials Conference on Alzheimer's Disease (CTAD)
November 12, 2013
Vice President, Research & Development Samuel Henderson, Ph.D., to Discuss Induced Ketosis in Mild to Moderate Alzheimer's Disease
Broomfield, CO, November 11, 2013 – Accera, Inc., a privately-held, commercial-stage healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today that Samuel Henderson, Ph.D., Vice President, Research & Development, will moderate and present at a symposium titled, "Metabolic Dysregulation in the Alzheimer Brain: Challenges and Opportunities," during the 6th Annual Clinical Trials Conference on Alzheimer's Disease (CTAD) in San Diego, CA. The symposium will take place on November 16, 2013 at 8:30 a.m. PT in the California Ballroom AB of the Westin Gaslamp Quarter.
Dr. Henderson will discuss the role of induced ketosis in mild to moderate Alzheimer's disease (AD). The symposium will also feature commentary from Stephen Cunnane, Ph.D., a metabolic physiologist at the University of Sherbrooke in Quebec, Canada, and Robert Krikorian, Ph.D., professor of clinical psychiatry and director of the division of psychology at the University of Cincinnati, on the metabolic deterioration of AD and dietary interventions that can reduce neurocognitive decline.
"I am delighted to participate in this symposium to investigate the role that metabolic dysregulation plays in Alzheimer's disease," said Dr Henderson. "Increasing evidence points to an early and progressive metabolic defect in the disease. Several studies will be presented to suggest that this may be a productive avenue for intervention at multiple stages of the disease. Further study will help to establish if this is a truly promising therapeutic target."
Accera's marketed product, Axona®, is a specially formulated, prescription-only medical food intended for the clinical dietary management of the metabolic processes associated with mild to moderate AD. It is the first proprietary commercialized AD therapy that addresses the well-recognized physiological hallmark of diminished cerebral glucose metabolism (DCGM) by inducing ketosis to provide an alternative energy source for brain cells.